Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5584354 | Experimental and Molecular Pathology | 2017 | 38 Pages |
Abstract
Multiple myeloma (MM) is characterised by intense protein folding and, consequently endoplasmic reticulum (ER) stress. The prostaglandin 15d-PGJ2 is able to raise oxidative stress levels within the cell and potentially trigger cell death. The aim of this study was to evaluate the antineoplastic effect of 15d-PGJ2 on MM in vitro and in vivo via ER and oxidative stress pathways. MM.1R and MM.1S cell lines were treated with 15d-PGJ2 at 1-10 μM and evaluated with regard to proliferation, mRNA expression of PRDX1, PRDX4, GRP78, GRP94, CHOP, BCL-2 and BAX. Stress data was validated via oxidized glutathione assays. MM.1R cells were inoculated into NOD/SCID mice, which were subsequently treated daily with 15d-PGJ2 at 4 mg/kg or vehicle (control), with tumour volume being monitored for 14 days. 15d-PGJ2 reduced cell proliferation, induced cell death and apoptosis at 5 μM and 10 μM and Stress-related genes were upregulated at the same doses. Oxidized glutathione levels were also increased. 15d-PGJ2 at 4 mg/kg in vivo halted tumour growth. In conclusion, 15d-PGJ2 induced myeloma cell death via ER stress in vitro. 15d-PGJ2 in vivo also inhibited tumour growth.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Marcelo Sperandio, Ana Paula D. Demasi, Elizabeth F. Martinez, Sara O. Saad, Fernando V. Pericole, Karla P. Vieira, Nadir S. Freitas, Vera C. Araújo, Amy Louise Brown, Juliana Trindade Clemente-Napimoga, Marcelo Henrique Napimoga,